ライフサイエンスコーパス: lethal dose

1 herwise lethal challenge with T3D (100 x 50% lethal dose).

2 a lethal dose of ZEBOV (30,000 times the 50% lethal dose).

3 st a lethal BoNT/A dose (1.05 times the 100% lethal dose).

4 tion against challenge infection with a high lethal dose.

5 therapeutic-intervention studies) the median lethal dose.

6 decreased survival time, and decreased mean lethal dose.

7 han WT mice following E. coli infection at a lethal dose.

8 nsient neurological symptoms emerging at sub-lethal doses.

9 of the animals to die at a dose of three 50% lethal doses.

10 sis model, the JPAB02 strain exhibited lower lethal dose 0 (LD0), LD50, and LD100, and dissemination

11 s, LNCaP, ALVA31, Du145, PC3, and PPC1, with lethal dose 50% approximately 1 micromol/L for CDDO-Me a

12 CFU of aerosolized Yersinia pestis CO92 (50% lethal dose, 6.8 x 10(4) CFU).

13 Mte bound and removed lethal doses (99.98%) of prions from inocula, effectivel

14 Based on these studies, the approximate lethal dose (ALD) exceeds 800 mug/dose and the NOAEL was

15 mutants displayed a dramatic increase in the lethal dose and in mean time-to-death.

16 ce expression was correlated with higher 50% lethal dose and less corneal scarring in vivo.

17 , kidney and urine and 25-fold-decreased 50% lethal dose and milder histopathological injury in hamst

18 . pestis CO92 infection and have similar 50% lethal doses and kinetics of infection with respect to c

19 s, resulting in nanomolar and low micromolar lethal doses and therapeutic indexes of 500 and 75, resp

20 f gK-myc in rabbit skin cells, increased 50% lethal dose, and decreased corneal scarring in ocularly

21 nd rGST-immunized hamsters were subjected to lethal doses, and the hamsters that survived showed seve

22 lenge with approximately 1,000 times the 50% lethal dose ( approximately 1,000x LD(50)) of B. anthrac

23 Virulence 50% lethal dose assays and serial sacrifice experiments furt

24 eceived doses 2857 times the estimated human lethal dose by injection.

25 gain full protection against the subsequent lethal-dose challenge with wild-type MYXV.

26 o possessed enhanced protection against high lethal dose challenges against homologous A/PR/8/34 and

27 ce infected with the equivalent of 80 median lethal doses cleared the organism.

28 L-6-treated mice, showed greatly reduced 50% lethal doses compared to wild-type (WT) mice.

29 of the same population were irradiated with lethal doses compared with their parental mitochondrial-

30 Intravenous TNF-alpha administration at near-lethal doses did not reactivate MCMV.

31 However, the estimated lethal dose during acute toxicity tests may only be a pa

32 protection from lethal challenge (1,000 50% lethal doses) equal to that of the wild-type virus.

33 nterocolitica infection were assessed in 50% lethal dose experiments.

34 The median lethal dose for 12-mum particles was 4.9-fold greater th

35 re resistant to hyperoxia-induced mortality (lethal dose for 50% of mice, 152 vs. 108 h).

36 a) led to a 130,000-fold increase in the 50% lethal dose for mice relative to that of the KIM5 parent

37 h, even though this would have constituted a lethal dose for the parental KIM/D27 strain.

38 ment, determining lethality with log(10) 50% lethal doses for each PTV genotype as follows (L/M/S con

39 dney tissue ( approximately 10(9) 50% embryo lethal doses/g) from 1-day-old chickens infected intrave

40 n up by A. cavernicola with no evidence that lethal dose has been reached in our working conditions.

41 a heretofore unknown deleterious role during lethal dose IAV infections by limiting the CD8 T cell re

42 in OG1RF showed a considerably increased 50% lethal dose in a mouse peritonitis model, and, at high i

43 entity, distinguished only by the compound's lethal dose in animals.

44 mutant exhibited a >3,000-fold-increased 50% lethal dose in mice.

45 The lethal dose in these hosts varied by 4 logs and was asso

46 s as well as the determination of the median lethal dose in two-day old chickens.

47 showed autolysis and retention of (210)Po at lethal doses in several organs.

48 umulate to greater numbers within the LNs of lethal dose-infected mice.

49 T cells alters the mortality associated with lethal dose influenza virus infections.

50 uch less important, even under conditions of lethal dose inoculum.

51 A striking effect of ET at lethal doses is adrenal necrosis.

52 Oral 50% lethal dose (LD(5)(0)) analyses showed that the NTS vacc

53 y neurovirulent in 21 day-old mice, with 50% lethal dose (LD(5)(0)) values of 0.1 and 0.5 log(1)(0) P

54 ministered i.n. but actually reduced the 50% lethal dose (LD(50)) by 3 orders of magnitude when the s

55 virulent phenotype as demonstrated using 50% lethal dose (LD(50)) experiments in mice.

56 The 50% lethal dose (LD(50)) for young B10.T(6R) mice was approx

57 y determination of the intracranial (IC) 50% lethal dose (LD(50)) in mice.

58 is significantly attenuated in mice; the 50% lethal dose (LD(50)) intranasally (i.n.) is >10,000-fold

59 For RJHM, the 50% lethal dose (LD(50)) is <10(1.3) in wild-type mice and 1

60 After establishing a median lethal dose (LD(50)) of 2,772 colony forming units (cfu)

61 dose-dependent manner with a calculated 50% lethal dose (LD(50)) of 680 PFU, whereas there were no d

62 nfection by the Ames strain, because the 50% lethal dose (LD(50)) of a PA-deficient (PA(-)) Ames muta

63 ollowing intranasal inoculation with 10x 50% lethal dose (LD(50)) of vaccinia virus strain IHD-J.

64 Administration of either the 50% lethal dose (LD(50)) or 10x LD(50) of Salmonella enteric

65 an approximately 90-fold increase in the 50% lethal dose (LD(50)) relative to the Yfe(+) Feo(+) paren

66 isplayed an approximately 24-fold-higher 50% lethal dose (LD(50)) than transport mutants.

67 uated 100-fold compared to the published 50% lethal dose (LD(50)) values for B. anthracis Ames after

68 ard toxicity metrics rodent liver TD(50) and lethal dose (LD(50)), Ames tests, and Comet assays for i

69 which was 100,000-fold greater than the 50% lethal dose (LD(50)).

70 onkeypox virus challenge of 65 times the 50% lethal dose (LD(50)).

71 den and to a significant increase in the 50% lethal dose (LD) after subcutaneous infection.

72 were completely protected against a 10x 50% lethal dose (LD) challenge of Streptococcus pneumoniae a

73 lly administered OTP reduced death caused by lethal dose (LD)(100/30) radiation by 50%.

74 vival during the first few days after median lethal dose (LD)100 and LD50 infection, while overall mo

75 rom a dose equivalent to 1,000 to 10,000 50% lethal doses (LD(50)) of BoNT/A when given three or four

76 n by the intraperitoneal route at as two 50% lethal doses (LD(50)).

77 is CO92 strain when it was given as five 50% lethal doses (LD(50)).

78 The 50% lethal doses (LD(50)s) for the Deltahcp2 through Deltahc

79 The 50% lethal doses (LD(50)s) of the Deltacrp and araC P(BAD) c

80 ainst intraperitoneal challenge with 200 50% lethal doses (LD(50)s) of virulent Streptococcus pneumon

81 2 Deltailp had a 55-fold increase in the 50% lethal dose ([LD(50)] 1.64 x 10(4) CFU) compared to the

82 faH mutant strain is attenuated in mice (50% lethal dose [LD(50)], >10(8) CFU).

83 The 50% lethal dose (LD50) and mean time to death (MTD) of the m

84 he latter being unable to kill mice at a 50% lethal dose (LD50) equivalent to 6,800 LD50s of WT CO92.

85 Our results suggest that the 50% lethal dose (LD50) falls within the range of 5 x 10(6) t

86 We estimated that the 50% lethal dose (LD50) for cervidized transgenic mice would

87 SPBNgamma has a 50% lethal dose (LD50) more than 100-fold greater than SPBN(

88 he ompX mutant survived, compared to the 50% lethal dose (LD50) of 1.2 x 10(3) CFU for the wild-type

89 increased mortality, with an approximate 50% lethal dose (LD50) of 10(5) CFU, while an equivalent dos

90 We found that Stx2a had a 50% lethal dose (LD50) of 2.9 mug, but no morbidity occurred

91 niformly lethal to these animals, with a 50% lethal dose (LD50) of 5.3 x 10(-2) 50% tissue culture in

92 teins exhibit resistance to 10,000 times the lethal dose (LD50) of BoNT/A, and transfusion of these r

93 eritoneally (i.p.) with 10,000 times the 50% lethal dose (LD50) of gp-adapted EBOV, and naive gps wer

94 Measuring the lethal dose (LD50) of HMCLs revealed that HMCLs displaye

95 apoptosis of primary leukemia samples with a lethal dose (LD50) of less than 10 microM in 16 of 27 (6

96 is study was aimed at determining the median lethal dose (LD50) of the Bacillus anthracis Ames strain

97 tant in the blue gourami fish model: the 50% lethal dose (LD50) of the DeltaeseJ mutant is 2.34 times

98 The 50% infectious dose (ID50) and lethal dose (LD50) of virus were estimated to be <1 and

99 The 50% lethal dose (LD50) values of these strains are increased

100 is substitution alone demonstrated log10 50% lethal dose (LD50) values too great to be measured.

101 The median lethal dose (LD50) was determined to be 0.015 50% TCID50

102 trated no toxicity up to 500-fold of the 50% lethal dose (LD50) when it was injected systemically.

103 intranasal (i.n.) challenge with ~240 median lethal doses (LD50) (2.4 x 10(4) CFU) of Y. pestis KIM6+

104 oculum of 2 x 10(7) bacteria resulted in 50% lethal doses (LD50) in neonatal DBA/2 mice.

105 glC, and subsequently challenged with 10 50% lethal doses (LD50) of aerosolized highly virulent F. tu

106 and protected BALB/c mice against 10,000 50% lethal doses (LD50) of S. Typhimurium or S. Enteritidis,

107 eumonic plague at a dose equivalent to 5 50% lethal doses (LD50) of wild-type (WT) CO92.

108 SCHU S4 at doses ranging from 50 to 500 50% lethal doses (LD50).

109 Swiss-Webster mice, challenged with five 50% lethal doses (LD50s) of anthrax spores, were given a sin

110 nimals dying within 2 to 3 days with two 50% lethal doses (LD50s) of the WT bacterium.

111 intraperitoneal spore challenge with 24 50% lethal doses [LD50s] of B. anthracis Sterne and against

112 ity and are completely protected following a lethal-dose MHV-1 challenge despite mounting only a mode

113 for each serotype is 1 mouse intraperitoneal lethal dose (MIPLD(50)) corresponding to 31 pg of BoNT/A

114 humoral responses upon equivalent 50% mouse lethal dose (MLD(50)) challenges with influenza virus.

115 The mean lethal dose (MLD) for pneumonic plague in guinea pigs wa

116 is highly dangerous with an estimated human lethal dose of 0.1-1 mug/kg body weight.

117 With a lethal dose of 1 ng kg(-1), they pose a biological hazar

118 ine the basis of the 1000-fold difference in lethal dose of 2 C. psittaci 6BC strains in mice.

119 2 inocula: a survivable dose of 50 PFU and a lethal dose of 500 PFU.

120 influenza virus infection, we determined the lethal dose of a highly pathogenic H5N1 virus (A/Hong Ko

121 previously shown that mice challenged with a lethal dose of A/Puerto Rico/8/34-OVA(I) are protected b

122 h before the ferrets were inoculated with a lethal dose of A/Vietnam/1203/04 (H5N1) influenza virus.

123 /Singapore/3/97(H5N3) then inoculated with a lethal dose of A/Vietnam/1203/04(H5N1) (Viet/1203/04).

124 CXCR2 knockout mice exposed to a median lethal dose of acetaminophen had a significantly lower m

125 bodies that completely protected them from a lethal dose of aerosolized RT.

126 ression in mice protected the mice against a lethal dose of agonistic anti-Fas antibody (P < .001) an

127 argeting only one population of cells with a lethal dose of alpha-particles, a decreased bystander mu

128 an approximately twofold decrease in the 50% lethal dose of B. anthracis spores administered in the p

129 higher survival rates when challenged with a lethal dose of B. pseudomallei.

130 bs) that were found to be protective against lethal dose of BoNT/A.

131 protects mice from systemic infection with a lethal dose of C. albicans, and deficiency of dectin-1,

132 All SCIDbgMN mice orally infected with a lethal dose of C. parvum survived after they were inocul

133 )CCH(2)CH(2)CH(2)CH(2)CH(3))(2)Cl(2)] (1), a lethal dose of cisplatin was delivered specifically to p

134 ute toxicity (convulsion and lethality) of a lethal dose of cocaine (180 mg/kg).

135 rotect mice from a subsequently administered lethal dose of cocaine, suggesting the enzyme may have t

136 t this, we infected BALB/c mice with 0.1 50% lethal dose of DeltaactA or virulent L. monocytogenes an

137 Flies co-injected with a non-lethal dose of Destruxin A and the normally innocuous Gr

138 RK5 KO mice following a sublethal dose, at a lethal dose of E. coli, the bacterial burdens remained h

139 macaques infected 24 hours previously with a lethal dose of Ebola virus suppressed viral loads by mor

140 ival time of rhesus macaques infected with a lethal dose of Ebola virus, although it failed to alter

141 livered 1, 2 or 3 days post-challenge with a lethal dose of EBOV.

142 on mice against challenge with an otherwise lethal dose of either F. tularensis LVS or a fully virul

143 tious units of VRP-GFP and challenged with a lethal dose of FMDV 24 h later were protected from death

144 g Tfrc and protecting 70% of cells against a lethal dose of H(2)O(2).

145 ice were able to confer protection against a lethal dose of H1N1 influenza virus A/Puerto Rico 8/34 (

146 s and protects mice against challenge with a lethal dose of H3N2 and H7N7 viruses.

147 /8/34 (PR8) and 5 wk later challenged with a lethal dose of heterologous pH1N1.

148 When challenged with a lethal dose of heterologous PR8 virus, X31-sciIV-primed

149 Ferrets exposed to an otherwise lethal dose of highly pathogenic avian influenza H5N1 we

150 immunodeficient mice being challenged with a lethal dose of HSV-1.

151 Mice inoculated intravaginally with a lethal dose of HSV-2, and treated with PLGA NPs, showed

152 ls, healthy mice, and mice challenged with a lethal dose of IFV A/PR/8/34 (H1N1) or A/Victoria/3/75 (

153 ine protected mice against a single high and lethal dose of influenza A virus but was ineffective aga

154 Mice were subsequently challenged with a lethal dose of influenza A/PR/8/34 virus 24 h after the

155 ) BALB/c mice were first infected with a non-lethal dose of influenza virus A (H/HKx31).

156 luenza virus, as measured by protection to a lethal dose of influenza virus, which is consistent with

157 eated and then challenged with an ordinarily lethal dose of IOE.

158 preconditioned by protocols not including a lethal dose of irradiation.

159 In a subsequent study, a lethal dose of LeTx with an equimolar nonlethal ETx dose

160 rather than caspase-1 protected mice from a lethal dose of lipopolysaccharide.

161 dition, Gsdmd(-/-) mice are protected from a lethal dose of lipopolysaccharide.

162 hepcidin pretreatment protected mice from a lethal dose of LPS and that hepcidin-knockout mice could

163 hepcidin pretreatment protected mice from a lethal dose of LPS and that hepcidin-knockout mice could

164 for IL-1beta and IL-18 were protected from a lethal dose of LPS by pretreatment with HMGB1-neutralizi

165 -specific GCN2KO mice were challenged with a lethal dose of LPS intraperitoneally (i.p.).

166 resolution of lung inflammation induced by a lethal dose of LPS or by Pseudomonas bacterial pneumonia

167 r leakage, and promoted survival following a lethal dose of LT.

168 ment 24 h before intranasal infection with a lethal dose of LVS (10,000 CFU) significantly decreased

169 nd when challenged 4 or 8 weeks later with a lethal dose of LVS i.n., they were 100% protected from i

170 acaca mulatta) infected intravenously with a lethal dose of lymphocytic choriomeningitis virus (LCMV)

171 ing aerosol exposure of rhesus macaques to a lethal dose of Marburg virus.

172 l vaccinated subjects after challenge with a lethal dose of MARV Angola.

173 ed splenocytes rescued allorecipients from a lethal dose of mouse CMV (MCMV) administered on day 0 in

174 E-R(ER) of FVB/N male mice challenged with a lethal dose of paraoxon, with complete elimination of sh

175 Mice were challenged with a lethal dose of PLA2 to evaluate protection against anaph

176 otect mice from future challenge with a near-lethal dose of PLA2.

177 Burn wounds were topically inoculated with a lethal dose of Pseudomonas aeruginosa 6 days after injur

178 We delivered a lethal dose of purified fluorescently-labeled ricin to m

179 Intratracheal instillation of a lethal dose of ricin (20 microg/100 g body weight) resul

180 A lethal dose of ricin caused accumulation of proinflammat

181 The kidneys of mice instilled with a lethal dose of ricin showed accumulation of fibrin/fibri

182 c1, in mice protects them from an ordinarily lethal dose of rickettsiae.

183 icient mice after injection of a potentially lethal dose of RVV.

184 expression in vitro and protect mice from a lethal dose of S. aureus by sequestering the AIP signal.

185 he survival status in mice challenged with a lethal dose of S. aureus.

186 el of infection, curing mice infected with a lethal dose of S. aureus.

187 strain L81905 or intranasal challenge with a lethal dose of S. pneumoniae A66.1 in a pneumonia model.

188 nt, mice were challenged intranasally with a lethal dose of S. pneumoniae D39.

189 Upon challenge with a lethal dose of SARS-CoV, virus-specific memory CD8 T cel

190 upon request, received a prescription for a lethal dose of secobarbital (35.1% of the 114 patients w

191 lovibrio injection of zebrafish containing a lethal dose of Shigella promotes pathogen killing, leadi

192 1 pathway suppressed cell death induced by a lethal dose of short-wavelength UV light, and high dosag

193 to protect A/J mice against 10 times the 50% lethal dose of Sterne strain spores introduced subcutane

194 imilar amongst the dietary treatments, a sub-lethal dose of Streptococcus iniae was administered to h

195 y-five rhesus monkeys were challenged with a lethal dose of SUDV.

196 to animals after subsequent challenge with a lethal dose of the control strain.

197 The 50% lethal dose of the Delta sod15 Delta sodA1 strain was si

198 rvival of mice infected intradermally with a lethal dose of the LVS was slightly improved by deletion

199 naive rats challenged intratracheally with a lethal dose of the virulent type A strain SCHU S4.

200 otection against challenge with an otherwise lethal dose of the wild-type RABV.

201 d IL-18 was confirmed in mice subjected to a lethal dose of TNF, or to a lethal CLP procedure.

202 on of the HSC pool and 100% survival after a lethal dose of total-body irradiation (TBI).

203 ra25 strain are able to survive an otherwise lethal dose of Toxoplasma tachyzoites and that complemen

204 In this study a non-lethal dose of UVC is shown to increase SHMT1 IRES activ

205 others were challenged orogastrically with a lethal dose of V. cholerae.

206 ected mice against the intranasal route of a lethal dose of vaccinia virus challenge.

207 d conferred protection from challenge with a lethal dose of vaccinia virus.

208 nd extend survival of mice challenged with a lethal dose of virus.

209 ble to protect mice against challenge with a lethal dose of virus.

210 id-ethyl amide provided before exposure to a lethal dose of whole-body irradiation protected WT mice

211 d them from paralysis after challenge with a lethal dose of wild-type poliovirus.

212 DeltaPGM mutant and later challenged with a lethal dose of WT S. iniae survived.

213 /6 and BALB/c mice survived challenge with a lethal dose of ZEBOV (30,000 times the 50% lethal dose).

214 animals were subsequently challenged with a lethal dose of ZEBOV.

215 us macaques were challenged with a uniformly lethal dose of ZEBOV; 11 of these monkeys were treated b

216 stered 6 hours after exposure to a uniformly lethal dose of ~20 LD(50) to prevent death and eliminate

217 and intranasally challenged 24 h later with lethal doses of AA60 or Sw06.

218 ats after nose-only inhalational exposure to lethal doses of aerosolized Francisella tularensis subsp

219 notypic phenomenon of tolerance to otherwise lethal doses of antimicrobials and to other antimicrobia

220 ection from inhalational challenge with 100% lethal doses of B. mallei and B. pseudomallei.

221 of a culture which is tolerant to killing by lethal doses of bactericidal antibiotics.

222 hese red blood cells are resistant to highly lethal doses of BoNT/A.

223 tected mice challenged with 280 mouse median lethal doses of BoNT/H at a mAb dose as low as 5 microg

224 uggests that the adaptation occurring at sub-lethal doses of carvacrol is different from that occurri

225 that can provide protection against multiple lethal doses of chemical warfare nerve agents in vivo.

226 Short-term fasting protects mice from lethal doses of chemotherapy through undetermined mechan

227 sed survival of recipient mice infected with lethal doses of clinically relevant opportunistic pathog

228 When challenged with 240 50% lethal doses of DENV2, mice given a single inoculation o

229 We used sublethal and lethal doses of E. coli to examine the mechanistic diffe

230 HCRs and neutralized challenge by 10,000 50% lethal doses of each of the seven BoNT serotypes.

231 Animals were injected intravenously with lethal doses of Escherichia coli or saline and sacrifice

232 The initial study compared similarly lethal doses of ETx (n=8) or LeTx (n=15) alone.

233 Combining either similar weight or lethal doses of ETx and LeTx increased the hazard ratio

234 d mice from subsequent challenge with highly lethal doses of F. novicida.

235 r wild-type littermates when challenged with lethal doses of F. novicida.

236 rescues hematopoietic progenitor cells from lethal doses of gamma radiation.

237 nt protection against subsequent exposure to lethal doses of H(2)O(2).

238 oses of HA22-LR at least 10-fold higher than lethal doses of HA22, and these higher doses exhibited m

239 rotected the mice, that were challenged with lethal doses of highly pathogenic influenza A H5N1 or H1

240 In vivo, CRP rescues mice challenged with lethal doses of histones by inhibiting endothelial damag

241 virus protected mice against challenge with lethal doses of homologous (VN1203; clade 1) and antigen

242 V5-H5) provides sterilizing immunity against lethal doses of HPAI H5N1 infection in mice.

243 ubtype provided sterilizing immunity against lethal doses of HPAI H5N1 infection in mice.

244 ery potently protected FCGR2A mice from near lethal doses of IgG ICs.

245 th this virus were completely protected from lethal doses of infection with either influenza virus or

246 gnificantly protect mice from infection with lethal doses of influenza viruses when orally administer

247 es survival when animals are challenged with lethal doses of influenza.

248 in a temporally segregated manner such that lethal doses of ionizing irradiation, if administered ov

249 saster may result in exposure to potentially lethal doses of ionizing radiation (IR).

250 C57Bl6 mice were exposed to sublethal and lethal doses of irradiation and were subsequently given

251 prevent cell death, and protect mice against lethal doses of irradiation.

252 Here we demonstrate that mice infected with lethal doses of L. monocytogenes produce higher levels o

253 d the mice from in vivo challenge with 3 50% lethal doses of LeTx.

254 ase increased survival in mice injected with lethal doses of lipopolysaccharide.

255 ction of these scFvs to specifically deliver lethal doses of liposome-encapsulated small molecule dru

256 8 immunized mice after being challenged with lethal doses of live PR8 virus.

257 LPS-induced TNF and the mortality induced by lethal doses of LPS.

258 ed, casp1 knockout (casp1(-/-)) mice survive lethal doses of LPS.

259 ignificantly improved survival of mice after lethal doses of LPS.

260 suckling mice against challenge with 25 50% lethal doses of mouse neurovirulent DENV-4 strain H241.

261 cyte responses and fully protected mice from lethal doses of MPXV.

262 articular, a complete protection against the lethal doses of paraoxon was observed with nano-OPH admi

263 Manganese (Mn) protects cells against lethal doses of purified Shiga toxin by causing the degr

264 saligenyl monophosphates designed to deliver lethal doses of radiation to cancer cells.

265 ignificant hypothermia in Tg mice exposed to lethal doses of SEB.

266 tered before or soon after acute exposure to lethal doses of soman, sarin, or paraoxon effectively an

267 tored the susceptibility of knockout mice to lethal doses of Stx2.

268 ngly, these mice were partially resistant to lethal doses of tachyzoites.

269 clones that survived exposure to ordinarily lethal doses of TcdB.

270 tects guinea pigs from the acute toxicity of lethal doses of the nerve agents soman and sarin, and of

271 for the wild-type spores even though the 50% lethal doses of the two strains were similar.

272 multidose schedule protected rodents against lethal doses of total body irradiation up to 13 Gy, whet

273 ns for the management of patients exposed to lethal doses of total body radiotherapy, but not doses h

274 ns for the management of patients exposed to lethal doses of total-body radiotherapy, but not doses h

275 roups of mice survived (100%) challenge with lethal doses of toxin.

276 fully protected mice against challenge with lethal doses of toxinogenic unencapsulated Sterne 7702 s

277 disease following intranasal challenge with lethal doses of vaccinia virus.

278 unization, mice were challenged with 100 50% lethal doses of virulent S. pneumoniae WU2.

279 red with wild-type mice when challenged with lethal doses of virus, correlating with increased expres

280 ence of YopM significantly increased the 50% lethal dose only in the intradermal model, suggesting a

281 gely on the determination of an acute median lethal dose or concentration.

282 ight and 3.1+/-1.0 vs. 3.9+/-1.5 for similar lethal doses; P=.5 for both).

283 valent to 21 to 43 times the estimated human lethal dose; pretreatment serum from the fourth epidemio

284 peritoneal challenge with 1,000 times the WT lethal dose produced only 2.5% mortality.

285 Lethal dose ranges (0%-100% lethality) of ETx (200-800 m

286 duction and weight gain were observed at sub-lethal dose rates.

287 conditions to estimate the probability of a lethal dose, showing that not all reservoirs with detect

288 y of M. acridum against acridids by reducing lethal dose, time to kill and food consumption.

289 e resistant to virus than CD1(-/-) mice (50% lethal dose titers: wild-type mice, 10 PFU; CD1(-/-) mic

290 Lethal dose to kill 50% of the test population values of

291 These mice were protected against a lethal-dose toxin challenge, but Ty21a-vaccinated mice w

292 exposures of at least three times the median lethal dose value.

293 ed liposomes are most cytotoxic, with median lethal dose values, after 24 h of incubation, equal to 1

294 nchiseptica strains, as measured by the mean lethal dose, varied widely.

295 enuation was achieved but the protective and lethal doses were too similar.

296 ith wild-type F. novicida (100 and 1,000 50% lethal doses) were highly protected (83% and 50% surviva

297 ction (60%) than the WT bacterium at two 50% lethal doses, which resulted in 100% mortality within 48

298 lone were challenged with 10(6) CFU (one 50% lethal dose) wild-type V. cholerae O1 El Tor strain N169

299 =50 ag of hamster PrPSc (approximately 0.003 lethal dose) within 2-3 d.

300 thology in lung, yet sterilising immunity to lethal dose WT challenge was achieved after low dose (20